Cureus . Effectiveness of COVID-19 Convalescent Plasma Infusion Within 48 Hours of Hospitalization With SARS-CoV-2 Infection

[tetano]

Cureus


. 2021 Jul 30;13(7):e16746.
doi: 10.7759/cureus.16746. eCollection 2021 Jul.
Effectiveness of COVID-19 Convalescent Plasma Infusion Within 48 Hours of Hospitalization With SARS-CoV-2 Infection


Natalia Lattanzio ¹ , Cristina Acosta-Diaz ¹ , Ricardo J Villasmil ¹ , Zachary Kirkland ¹ , Caitlin Bass ² , Sage Yenari ³ , Jorge Conte ¹ , Kevin Dawkins ¹ , Tamela Fonseca ⁴ , Cindy Grimes ² , Angie Stewart ⁵ , Mary E Geary ⁶ , Harold Vore ⁷ , Karen Hamad ¹ , Wilhelmine Wiese-Rometsch ¹ , James Fiorica ⁸ , Manuel Gordillo ⁹ , Roberto Mercado ⁹ , Kirk Voelker ¹⁰



Affiliations

• PMID: 34513370
• PMCID: PMC8405359
• DOI: 10.7759/cureus.16746

Abstract

On January 30, 2020, the World Health Organization (WHO) declared the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic a worldwide emergency. Worldwide there have been 170 million cases of the resulting disease coronavirus 2019 (COVID-19), of those, 3.53 million have resulted in death. The Food and Drug Administration (FDA) with Mayo Clinic as the lead institution authorized COVID-19 convalescent plasma (CCP) for treatment of SARS-CoV-2 infection. Effective therapeutic window for CCP administration had yet to be defined. We addressed this gap by characterizing longitudinal biologic response and clinical outcomes of COVID-19 patients treated with CCP. Primary outcome was discharged to home/home health.

Keywords: convalescent plasma; covid-19; discharge to home; infusion; sars-cov-2.